Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)

NCT06621095 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
First-line
Metastatic Pancreatic Cancer

Interventions

DRUG: anlotinib + benmelstobart + nab-paclitaxel + gemcitabine
DRUG: nab-paclitaxel + gemcitabine

Sponsor

RenJi Hospital

Collaborators

[object Object]